[
  {
    "ts": null,
    "headline": "Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q1 2025 Update",
    "summary": "Prem Watsaâs 13F portfolio grew to $1.84B in Q1 2025. Check out Fairfax Financial Holdings' top holdings and strategic stake increases.",
    "url": "https://finnhub.io/api/news?id=2a41c3d546866670a6e8771b642aec1a016afd1b90cc367a0f011d88ad00254d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749420435,
      "headline": "Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q1 2025 Update",
      "id": 135117078,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1264256639/image_1264256639.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Prem Watsaâs 13F portfolio grew to $1.84B in Q1 2025. Check out Fairfax Financial Holdings' top holdings and strategic stake increases.",
      "url": "https://finnhub.io/api/news?id=2a41c3d546866670a6e8771b642aec1a016afd1b90cc367a0f011d88ad00254d"
    }
  },
  {
    "ts": null,
    "headline": "3 Stocks With Mouthwatering Dividends You Can Buy Right Now",
    "summary": "AbbVie is a Dividend King with a strong product lineup.  Bristol Myers Squibb offers a high dividend yield and has underrated growth potential.  Pfizer's dividend and underlying business are safer than they might seem at first glance.",
    "url": "https://finnhub.io/api/news?id=c8fe68255b6f1ad7726da68a63c4b166af8169a6def864a6b8bdd0d99767d984",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749378900,
      "headline": "3 Stocks With Mouthwatering Dividends You Can Buy Right Now",
      "id": 135114218,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "AbbVie is a Dividend King with a strong product lineup.  Bristol Myers Squibb offers a high dividend yield and has underrated growth potential.  Pfizer's dividend and underlying business are safer than they might seem at first glance.",
      "url": "https://finnhub.io/api/news?id=c8fe68255b6f1ad7726da68a63c4b166af8169a6def864a6b8bdd0d99767d984"
    }
  }
]